RecruitingNCT03529617

Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates

Sponsor

Universitaire Ziekenhuizen KU Leuven

Enrollment

60 participants

Start Date

Oct 19, 2016

Study Type

OBSERVATIONAL

Conditions

Critically Ill Patients Pharmacokinetics Liposomal Amphotericin B

Summary

This prospective study will compare the pharmacokinetic exposure to liposomal amphotericin B between critically ill patients and non-critically ill (hematology) patients in an early and late exposure day.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Treatment with L-AmB
Admitted to an ICU or Hematology ward

Exclusion Criteria3

DNR 2 or 3
Pregnant or lactating women
Previous documentation of intolerance/sensitivity to L-AmB

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSample collection

Plasma, urine, BAL and ascitic fluid sample collection.

Locations(1)

UZ Leuven

Leuven, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03529617

Related Trials

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

NCT074222854 locations

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

NCT065007931 location